• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The renal elimination of rifampicin as a function of the oral dose. A convenient way to assess relative bioavailability.

作者信息

Brechbühler S, Fluehler H, Riess W, Theobald W

出版信息

Arzneimittelforschung. 1978;28(3):480-3.

PMID:580761
Abstract

A spectrophotometric method for the quantitative determination of rifampicin in urine is described and its specificity and precision are discussed. It is shown that the mean cumulative urinary elimination of rifampicin is reproducible when the same dose is administered twice in two different experiments to the same group of volunteers. The percentage of the amount eliminated increases with increasing dose. The renal elimination of apparent rifampicin can be used as a parameter for assessment of relative bioavailability of rifampicin from oral dosage forms of the same nominal strength if an appropriate number of volunteers is involved in the test.

摘要

相似文献

1
The renal elimination of rifampicin as a function of the oral dose. A convenient way to assess relative bioavailability.
Arzneimittelforschung. 1978;28(3):480-3.
2
The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.利用尿排泄数据评估固定剂量复方抗结核制剂中利福平相对生物利用度的可能性。
Int J Tuberc Lung Dis. 2001 Aug;5(8):691-5.
3
Bioavailability of rifampicin caplets (600 mg and 450 mg) in healthy Indonesian subjects.
Int J Clin Pharmacol Ther Toxicol. 1986 Feb;24(2):60-4.
4
Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.利福平、异烟肼和吡嗪酰胺在四种药物固定剂量组合与相同剂量水平的单独制剂中的相对生物利用度。
Int J Pharm. 2004 May 19;276(1-2):41-9. doi: 10.1016/j.ijpharm.2004.02.019.
5
The development of a standardised screening protocol for the in vivo assessment of rifampicin bioavailability.
Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S329-35; discussion S351-2.
6
Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.三联药物制剂中利福平、异烟肼和吡嗪酰胺的生物利用度:血浆和尿液动力学比较
Int J Tuberc Lung Dis. 1999 Feb;3(2):119-25.
7
Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.固定剂量复方胶囊中利福平、异烟肼和吡嗪酰胺的生物利用度。
Int J Tuberc Lung Dis. 1998 Oct;2(10):824-30.
8
[Urinary excretion of rifampicin in kidney failure when administered alone or together with isoniazid].
Antibiotiki. 1983 Sep;28(9):698-702.
9
The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency.
Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S322-4; discussion S351-2.
10
Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol.利福平、异烟肼和乙胺丁醇复方片剂与含利福平胶囊和含异烟肼及乙胺丁醇片剂联合给药的相对生物利用度。
Arzneimittelforschung. 1995 Nov;45(11):1236-9.

引用本文的文献

1
Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study.尿液比色法检测结核病治疗期间利福平低暴露:一项概念验证研究。
BMC Infect Dis. 2016 Jun 1;16:242. doi: 10.1186/s12879-016-1576-1.